23andMe Holding Co. (MEHCQ)

Market Cap	119.81M
Revenue (ttm)	189.90M
Net Income (ttm)	-280.89M
Shares Out	27.54M
EPS (ttm)	-10.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,279
Average Volume	466,383
Open	4.260
Previous Close	4.360
Day's Range	4.150 - 4.600
52-Week Range	0.470 - 6.210
Beta	1.99
RSI	55.68
Earnings Date	Jul 28, 2025

About 23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. It also operates Lemonaid telehealth platform to access affiliated licen...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 265
• Stock Exchange: OTCMKTS
• Ticker Symbol: MEHCQ

Financial Performance

In 2024, 23andMe Holding Co.'s revenue was $189.90 million, a decrease of -13.54% compared to the previous year's $219.64 million. Losses were -$280.89 million, -57.87% less than in 2023.